On the move?  by unknown
your hypothesis? What is the next step to obtain conclusive proof
that treatment of hypercholesterolemia into the low normal
range—and I should emphasize that the values shown here used to
be accepted as normal in the North American population B—de-
lays bioprosthetic SVD in large patient cohorts?
Dr Farivar. Dr Miller, thank you. This is the first report in
bioprosthetic valves, and to get to the truth, I think we need a
prospective randomized controlled trial. I would envision a
multicenter trial enrolling subjects who have implanted tissue
valves and subcritical coronary stenosis and are not receiving
statins. We should randomize them into two groups— one to
receive HMG-CoA reductase inhibitors and the other to receive
placebo—and to follow the progression of bioprosthetic tissue
valve calcium accumulation over 1 to 2 years, using methods
that are similar to a study recently published concerning the
native aortic valve. Shavelle and associates have recently
shown in the Lancet that statins reduce the accumulation of
calcium in the native aortic valve, as assessed by electron beam
computed tomographic scanning, for calcium in the valve. These
studies could be performed concurrently with surveillance scans of
the coronary arteries to determine whether statins also prevent the
progression of coronary calcification.
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